In spite of the established knowledge of the genetic alterations responsible for cancer onset, the genes promoting and maintaining the invasive/metastatic phenotype are still elusive. The MET proto-oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor (HGF), senses unfavorable micro-environmental conditions and drives cell invasion and metastasis. MET overexpression, often induced by tumor hypoxia, leads to constitutive activation of the receptor and correlates with poor prognosis. To establish the role of MET in different phases of tumor progression, we developed an inducible lentiviral delivery system of RNA interference. Silencing the endogenous MET gene, overexpressed in tumor cells, resulted in (i) impairment of the execution of the full invasive growth program in vitro, (ii) lack of tumor growth and (iii) decreased generation of experimental metastases in vivo. Notably, silencing MET in already established metastases led to their almost complete regression. This indicates that persistent expression of the MET oncogene is mandatory until the advanced phases of cancer progression.
Introduction
Tumorigenesis is a multi-step process, involving genetic events that activate oncogenes and inactivate tumor suppressor genes (Nowell, 1976; Lengauer et al., 1998) . Each of these events is linked to the acquisition of distinct malignant features, such as cell-autonomous proliferation, block of differentiation, immortalization, escape from apoptosis and acquisition of invasive ability. Metastasis is a complex process that occurs through several sequential, rate-limiting steps, including invasion of extracellular matrices, intravasation, transport and survival in the circulation, extravasation and growth in the secondary site. To successfully complete this program, metastatic cells have therefore to be endowed with several biological properties. Similar properties are shared with cells that during embryonic development undergo epithelial-mesenchymal transition to drive morphogenesis (Thiery, 2003) . It seems, then, that morphogenesis and metastasis evolve from the same genetic program, named 'invasive growth', that instructs the cells to leave a primary site, cross tissue boundaries and reach and survive in a new environment (Thompson et al., 2005) . During recent years, we have gained a reasonable knowledge about the genes involved in the first steps of cell transformation, but our understanding of the genetic and biochemical mechanisms mandatory to sustain late stages of tumor development and survival are still lacking.
A large body of experimental evidence has shown that specific extracellular factors can sustain the invasive growth program. Among them, a pivotal role is played by hepatocyte growth factor (HGF), the ligand for the tyrosine kinase receptor encoded by the MET protooncogene . Under physiological conditions, the coordinated accomplishment of the invasive growth program driven by MET is involved in a wide spectrum of biological processes, including the formation of epithelial tubular structures, myoblast migration and neurite branching (Rosario and Birchmeier, 2004) . However, deregulated activation of the MET-driven 'invasive-growth' program confers unrestricted proliferation and invasive/metastatic properties to cancer cells (reviewed by Comoglio and Trusolino, 2002; Danilkovitch and Zbar, 2002; Birchmeier et al., 2003; Corso et al., 2005; Gao and Vande Woude, 2005) .
The involvement of MET in human tumors is now firmly established, as germline missense mutations of this gene are responsible for hereditary forms of cancer (Schmidt et al., 1999; Lee et al., 2000) and inappropriate receptor activation has been observed in several types of solid tumors, often correlating with poor prognosis (Birchmeier et al., 2003) . Yet, the most frequent alteration of this oncogene in human cancers is receptor overexpression, leading to constitutive dimerization and activation, even in the absence of ligand (http://www. vai.org/vari/metandcancer). In most cases, increased MET expression is considered the consequence rather than the cause of cell transformation and can be due to enhanced transcription induced by activation of oncogenes, such as Ras, Ret and Ets (Gambarotta et al., 1996; Ivan et al., 1997) or to hypoxia-activated transcription (Pennacchietti et al., 2003) . The latter is considered as the most common cause of MET overexpression, and is triggered by the 'oxygen sensor' through activation of HIF1 (hypoxia inducible factor 1) (Pouyssegur et al., 2006) .
It is known that deregulated activation of the MET oncogene is critical, in some instances, for the acquisition of tumorigenic properties and, almost invariably, is required for the achievement of the invasive phenotype (Zhang and Vande Woude, 2003) . Not surprisingly, the same events promoted by this proto-oncogene in normal cells are also implicated in the xenophilic behavior of cancer cells during metastasis. In fact, during cancer progression, neoplastic cells must first modify the repertoire of their adhesive molecules to suppress the interactions with their neighbors, then detach from basement membrane and interact with the extracellular molecules of the new stromal compartment. The ability to recognize this new environment is strictly required for eluding 'anoikis' (that is apoptosis induced by loss of anchorage (Frisch and Screaton, 2001) ). Moreover, to invade, cancer cells must degrade the extracellular matrix. MET activation indeed remodulates the integrin repertoire, disrupts intercellular junctions and induces transcription and activation of matrix metalloproteinases (reviewed by Trusolino and Comoglio, 2002) . Furthermore, it has recently been shown that MET activation induces a cell-autonomous pro-coagulant activity that leads to pericellular fibrin deposition, thus creating a micro-environment that supports the growth of the tumor, favors the incoming of new vessels and is fertile for tumor cell expansion and survival (Boccaccio et al., 2005) . Experimental evidence in animal models demonstrates that ectopic overexpression of MET renders cells tumorigenic and metastatic in nude mice (Rong et al., 1994) , while MET or HGF transgenic expression results in development of spontaneous tumors and metastasis (Takayama et al., 1997; Wang et al., 2001) .
The role of MET in tumor progression toward metastasis has been exhaustively studied (Vande Woude et al., 1997; Birchmeier et al., 2003) . In our work, we directly address the requirement of MET expression ('addiction') in already established metastases, by using an inducible lentiviral RNA interference (RNAi) system. We show that, in spite of the many genetic lesions harbored by metastatic cells, MET silencing in already established metastases led to their almost complete regression.
Results

Generation and validation of a novel RNAi lentiviral inducible system
Tet-inducible strategies have been developed and used in a variety of biological systems to achieve tightly regulated expression of mRNA or shRNA (short hairpin RNA) (Corbel and Rossi, 2002) . As reported (van de Wetering et al., 2003) , the H1 promoter for RNA polymerase III, leading to shRNAs expression, contains sequences upstream to the transcription start site that are dispensable for the promoter activity. By PCR technology, we thus substituted these sequences with those of the Tet operator (TetO) and downstream to the mutated H1 promoter, we cloned the MET shRNA sequence, that we previously used to specifically silence MET (Pennacchietti et al., 2003) . We then moved the whole cassette into a lentiviral vector (pCCLsin. PPT.hPGK.GFP.Wpre), containing also green fluorescent protein (GFP) sequences under the control of a different and ubiquitous promoter (Supplementary Figure 1a) . As a control, we produced the same construct for a mismatched MET shRNA (C shRNA).
We validated this system in human cell lines. When 293T cells were transduced with MET shRNA vector alone (without TetR), shRNAs were produced independently from the presence of doxycycline and MET silencing was constitutive ( Figure 1a , lanes 7 and 8). The system became inducible when cells were transduced with the shRNA construct, together with the vector coding for the TetR. When TetR binds the TetO in the promoter, in fact, it sterically blocks shRNA transcription; in the presence of doxycycline, the TetR is displaced from the operator and the shRNA transcription can occur (Supplementary Figure 1a) . As shown, cells transduced with both TetR and MET shRNA viruses displayed an almost complete silencing of the protein upon 48 h of doxycycline treatment ( Figure 1a , lane 4), while MET levels were unaltered in the absence of doxycycline (lane 3) or in the presence of the control shRNA (lanes 1 and 2). MET silencing occurred in a time- (Figure 1b ) and dose-dependent manner ( Figure 1c) . Furthermore, this system is reversible, since removal of doxycycline from cells resulted, after 96 h, in the complete recovery of MET levels ( Figure 1d ).
MET silencing inhibits invasive growth 'in vitro'
We thus exploited this system to investigate the transforming and invasive role of MET. We studied GTL16 gastric carcinoma cells that overexpress the receptor, which is constitutively phosphorylated. This behavior is frequently observed in human carcinomas, where MET overexpression and constitutive activation are very common (Maulik et al., 2002) . In spite of the high levels of MET, our inducible system led to a strong decrease of both MET mRNA (Supplementary Figure  1b) and protein (Figure 2a, upper panel) in the presence of doxycycline. On MET silencing, we also observed impairment in activation of p42/44 mitogen-activated protein kinase (MAPK) and AKT, two downstream effectors of MET involved in the invasive (Grotegut et al., 2006) and anti-apoptotic response, respectively (Bardelli et al., 1999; Figure 2a) .
After testing the ability of this system to efficiently reduce the level of the MET protein in transduced cells, we aimed at evaluating their behavior. We showed that upon MET silencing, the growth ability of cells was severely impaired (Figure 2b ) as most of them stopped proliferating (proliferating cells were 38.74% in controls and 6.53% upon MET silencing) and were blocked in the G0-G1 phase of the cell cycle (Figure 2c) . Moreover, cells not expressing MET lost also their capacity to grow in anchorage-independent manner in soft agar Western blot analysis of MET protein levels in total cell lysates demonstrated that, in the presence of both TetR and MET shRNA, MET was silenced only upon doxycycline addiction. On the contrary, in the presence of TetR þ C shRNA, MET levels were normal. In the absence of TetR (MET shRNA lanes), the system is constitutive, and thus MET was silenced also in the absence of doxycycline. (b) MET silencing was induced by doxycycline in a time-dependent manner, as proven by doxycycline treatment for 12 or 24 h, and (c) in a dose-dependent manner, as demonstrated by treatment with 0,1 or 1 mg/ml of doxycycline. (d) Reversibility of the system: after 48 h of silencing, doxycycline was removed from the medium. Ninety-six hours later, normal MET levels were recovered. In the lower part of each panel, blots were probed with anti-actin antibodies as loading control. shRNA, short hairpin RNA.
Met overespression sustains metastasis persistence S Corso et al or C shRNA. Also in these cells, we were able to obtain an efficient MET silencing (Supplementary Figure 2a and data not shown) and inhibition of the invasive ability and of anchorage-independent growth (Supplementary Figures 2b and c).
To provide evidence that the observed effect was not due to silencing of specific genes (off-target effect), we expressed in GTL16 cells a different MET shRNA (Shinomiya et al., 2004) and we found that it was equally effective in silencing MET expression and in inhibiting MET-driven signal transduction (Supplementary Figure 3a) . Moreover, we observed that this shRNA was also able to interfere with cell growth and with the ability of the cells to form colony in soft agar ( Supplementary Figures 3b and c) .
Taken together, all these data suggest that silencing the endogenous MET in cells where it is overexpressed and constitutively active-like in many carcinomasresults in impairment of in vitro accomplishment of the invasive growth program.
MET silencing results in impaired tumor growth
To investigate if MET expression in tumor cells is required per se to sustain tumorigenesis, we analysed the in vivo effect of the MET functional knockout in xenografts. GTL16 cells, transduced with TetR and MET/C shRNA viruses and pretreated with doxycycline for 24 h, were subcutaneously injected in nude mice. During the whole experiment, MET silencing in tumor cells was maintained by oral administration of doxycycline to mice. As shown in Figure 3 , MET silencing severely impaired tumor growth, as proved by the dramatic reduction of both tumor burden ( Figure 3a ) and tumor weight (Figure 3b ). To evaluate if the observed tumor impairment was due to decreased tumor growth or to lack of tumor engraftment after injection, we subcutaneously injected shRNA-transduced cells but we started doxycycline treatment only when xenograft masses became visible (volume >15 mm 3 ). As shown in Figure 3c , also in these conditions MET silencing resulted in block of tumor growth. Moreover, we were able to show that MET silencing when the tumor was already grown, resulted in regression of the pre-existing tumor (Figure 3d) .
These results thus show that MET expression in xenograft cells is required for tumor development and maintenance. Similar in vivo results were obtained also with SUIT-2 cells (Supplementary Figure 2d) .
To verify that tumor reduction was accompanied by a decrease of MET activation in the tumor area, we and 'asterisk' groups, MET silencing was induced immediately, while in the 'open triangles' group doxycycline was added only after tumor engraftment (after 7 days, as indicated by the arrow). The insert shows at higher magnification the tumors behavior in the first days of the experiment. As shown, MET silencing interfered with tumor progression, thus indicating that the observed inhibition of tumor growth was not due to lack of engraftment. (d) To evaluate the effect of MET silencing on already grown tumors, doxycycline was added to the drinking water of mice when tumors had reached an average volume of 300 mm 3 (20th day). As shown, MET silencing induced the regression of the already established primary tumors. The difference between the 20th and 32nd days is statistically significant. On the contrary, tumors expressing control shRNA did not decrease their volume upon doxycycline treatment (data not shown). In all the panels, the asterisks indicate that the differences are statistically significant. shRNA, short hairpin RNA. stained serial tumor slices with an antibody directed against the activated form of MET (anti Phospho-MET). As shown in Figure 4a , MET was inactive in the majority of tumor cells. To prove that these cells were indeed the transduced ones, we took advantage from the presence of the GFP coding sequence in the same lentiviral vector controlling shRNA expression (Supplementary Figure 1a) . We thus stained adjacent slices with GFP antibodies and we observed that GFP-positive areas indeed matched those where MET was silenced. Interestingly, small areas displaying MET activation were negative for GFP expression. This is probably due to the presence, in the injected bulk cell population, of some not-transduced cells, which have been counterselected in vivo for their advantage for survival. As expected, in tumors derived from control shRNAs transduced cells, we detected MET activation in GFPpositive areas (Figure 4a ).
To investigate the mechanisms responsible for tumor growth impairment, we analysed tumor slices for the presence of apoptotic and proliferative markers and we observed that MET silenced areas (GFP þ ) matched to the non-proliferating regions ( Figure 4b) ; moreover, these areas were significantly more positive for TUNEL staining compared to GFP areas (Figures 4c and d) . These findings are in agreement with the decrease of MAPK and AKT activation demonstrated in METsilenced cells grown in vitro (Figure 2a) .
MET silencing impairs onset and maintenance of experimental metastasis
To investigate if MET activation is required for metastasis onset and maintenance, we performed a lung colony formation assay in nude mice. We injected transduced GTL16 cells, in which MET expression was either silenced or not, into mice tail veins. After 5 weeks, half of the mice in each experimental group were killed to evaluate lung colonies formation. This assay evaluates the ability of tumor cells to survive in the bloodstream, to extravasate, to home in a new environment and, eventually, to originate new tumor masses. Although it does not fully recapitulate the naturally occurring metastatic process it is, however, considered as a valuable experimental tool as it implies the ability of Met overespression sustains metastasis persistence S Corso et al tumor cells to accomplish most of the stages of the metastatic process (Gupta and Massague, 2006) . Lung slices were stained with haematoxylin and eosin (H&E) and classified in four pathological categories, spanning from colony-free sections to sections with extensive metastatic deposit ( Figure 5 ). Lungs of mice injected with MET expressing cells displayed numerous extensive metastatic deposits ( Figure 5, group b) , while those of animals receiving MET-silenced cells had only focal or no metastatic deposits ( Figure 5, group a) . The experiment was further continued and half of the remaining mice, previously untreated and displaying lung colonies (as group b), started doxycycline treatment. After 4 additional weeks, all the mice (never treated with doxycycline (group d), always treated with doxycycline (group c) or treated only for the last 4 weeks (group e)) were killed. As shown in Figure 5 , upon MET silencing, we observed regression of the previously detected lung colonies, while in untreated mice, the colonies continued to grow (group e vs d; Po0.01). In mice where MET was silenced along all the experiment length (group c), only a few and small colonies were observed in the lungs. No difference in the number of lung colonies was observed when mice were injected with cells transduced with C shRNA, independently from doxycycline treatment of the mice (data not shown).
Discussion
In this study, we have used a newly developed shRNA delivery system to target the MET oncogene in established carcinoma cells that, like many naturally occurring tumors, express high levels of endogenous MET protein. This experimental system is remarkably different from the inhibitory strategies developed so far, since it allows evaluation of the cell-autonomous effect of oncogene inhibition, independently from the perturbation of the tumor microenvironment. In fact, conventional inhibitors of MET-such as small tyrosine kinase inhibitors, antibodies or decoy molecules (Christensen et al., 2003; Kong-Beltran et al., 2004; Michieli et al., 2004; Petrelli et al., 2006; Smolen et al., 2006) -impair the activity of the receptor not only in tumors but also in host cells. This is critical, since MET functions have been linked also to neo-angiogenesis and host defense responses, as this oncogene is expressed in endothelial cells as well as in macrophages and in cells of the immune system (Bussolino et al., 1992; Galimi et al., 2001; Skibinski et al., 2001) . Here, we show that MET silencing in cancer cells resulted in suppression of the invasive growth program in vitro, as demonstrated by cell inability to invade surrounding matrices, grow and form anchorage-independent colonies. This impairment is due to both decreased proliferation and increased propensity to undergo apoptosis, mirrored by decreased activation of MAPK and AKT pathways upon MET silencing. We also found that, in vivo, in spite of the many genetic lesions harbored by the studied cancer cells (RegeCambrin et al., 1992; Di Renzo et al., 1995b), MET silencing resulted in severe impairment of both tumor establishment at the site of injection and tumor persistence. While it is somehow expected (and it has been reported in different experimental systems (Patane et al., 2006; Smolen et al., 2006; Taulli et al., 2006) that MET is required for the initial steps of invasion and metastasis, our data further demonstrate that expression of an activated MET is mandatory to elicit and sustain the clonogenic growth of metastatic colonies in the lung. Surprisingly, moreover, MET silencing in already established lung colonies led to their regression, revealing that MET expression is still enforced in the advanced phases of tumor progression. We thus suggest that the role of MET in driving metastasis is dual as it supports both metastatic spread and maintenance.
The critical role played by MET in metastasis can also be inferred by the data obtained from the analysis of human tumors. As previously mentioned, MET overexpression is very common in human carcinomas and cells overexpressing it are selected during cancer 6 cells/ mouse); mice were divided in the following experimental groups (6 mice/group), as schematized in the lower panel: (a) treated with doxycycline and killed after 4 weeks; (b) untreated and killed after 4 weeks; (c) treated and killed after 8 weeks; (d) untreated and killed after 8 weeks; (e) untreated for 4 weeks and then treated for the following 4 weeks. Slices of the whole lungs were stained with H&E and classified in the indicated four pathological grades. For the statistical analysis, grades 3 and 4 were considered positive for the presence of metastasis. Representative pictures of lung slices for each group are shown below the graphic. As shown, MET silencing inhibited lung colony onset (groups (a) and (c)) and induced regression of existing colonies (group (e) versus (d)). The asterisk indicates that the differences between the indicated groups are statistically significant. H&E, haematoxylin and eosin; shRNA, short hairpin RNA.
Met overespression sustains metastasis persistence S Corso et al progression. Notably, while the number of gene copies is usually normal in primary tumors, gene amplification is not rare in metastatic lesions (Di Renzo et al., 1995a) . This suggests that the continuous expression of this oncogene, even in advanced phases of tumor progression, is so critical that gene amplification confers a selective advantage and it is thus stably acquired. Moreover, it has been shown that MET activating mutations, preferentially driving pathways responsible for promoting invasion and protection from apoptosis, are specifically selected during metastasis, in humans (Di Renzo et al., 2000) .
Development of metastasis requires that tumor cells acquire properties, such as loss of cellular adhesion, increased motility and invasiveness, entry and survival in the circulation, exit into new tissue, and eventual colonization of a distant site (Chambers et al., 2002; Fidler, 2003) . Seminal work using experimental assays for metastasis demonstrated that rare cells within malignant cell populations are endowed with several of these metastasis-promoting functions (Fidler, 2003) . Several biological properties induced upon MET activation are mandatory for metastasis. In fact, activation of this receptor supports cell invasion-implying breakage of cell junctions, cell dissociation, motility, invasion of surrounding extracellular matrices-and the ability to overcome apoptosis due to lack of anchorage-the so called 'anoikis' (Birchmeier et al., 2003) . This multifaceted ability of MET has a mechanistic explanation in its signal transducing properties. The receptor, in fact, is known to concomitantly activate both the Ras-MAPK (Ponzetto et al., 1994; Fixman et al., 1995) and the phosphatidylinositide 3 0 -kinase-AKT pathways (Graziani et al., 1991) , together controlling growth, resistance to apoptosis and cytoskeletal rearrangement. Indeed, upon MET silencing, we observed a decrease of both MAPK and AKT activation, matching a strong decrease of proliferation and increase of the apoptotic rate.
It is widely accepted that tumor cells progressively undergo a series of genetic changes, each being linked to the acquisition of distinct malignant features, such as cell-autonomous proliferation, block of differentiation, immortalization, escape from apoptosis and acquisition of invasive ability. Thus, theoretical concerns were raised about the reversibility of the malignant phenotype as consequence of inactivation of a single oncogene. However, experimental evidence suggest that cancer cells become 'addicted' to these genetic changes and, thus, inhibition of activated genes results in either growth arrest or cell death (Chin et al., 1999; Felsher and Bishop, 1999; Huettner et al., 2000; Gunther et al., 2003) . Recent clinical experience proved that the concept of 'oncogene addiction' is true also for human tumors as shown, as an example, by the therapeutic targeting of the bcr-abl oncogene in Chronic Myelogenous Leukemia (Druker et al., 2001; Kantarjian et al., 2002; Vogel et al., 2002) . By using an inducible system of RNAi, here we show that human tumor cells overexpressing the endogenous MET gene are 'addicted' to this oncogene and that this 'addiction' is not restricted to primary tumor cells but it is still present in metastasis.
Altogether, our experiments demonstrate that MET is required not only for tumor and metastasis growth but also for their maintenance, suggesting MET targeting as a possible therapeutic approach to treat even late stagetumors, usually poorly responsive to current available therapies.
Materials and methods
Generation of plasmids for the inducible system shRNA inducible vector: by PCR technology we engineered the pSUPER plasmid, substituting the last portion of H1 promoter with TetO sequence in order to obtain the pSUPER TetO vector (van de Wetering et al., 2003) . We then inserted in pSUPER TetO (BglII, HindIII) the already published MET (5 0 -GUCAUAGGAAGAGGGCAU-3 0 ) and Control (5 0 -CU-CAUAGGAAGACCCCAUU-3 0 ) targeting sequences (Pennacchietti et al., 2003) and the MET221 (5 0 -GTGCAGTA TCCTCTGACAG-3 0 ) targeting sequence (Shinomiya et al., 2004) to obtain the pSuper TetO-shRNA. We moved (EcoRIHindIII) the entire construct in the BbsI site of the lentiviral vector pCCLsin.PPT.hPGK.GFP.Wpre (Taulli et al., 2005) . TetR vector: TetR sequence was obtained from pCDNA6/ TR and cloned (MscI, NheI) in the lentiviral vector p156RRLsin.PPThCMV.MCS.pre (Follenzi et al., 2000) under the control of cytomegalovirus promoter.
Cell culture
Cells were grown either in Dulbecco's modified Eagle's medium (293T) or RPMI (GTL16, SUIT-2) supplemented with 10% fetal bovine serum. Doxycycline (doxy) was used at a concentration of 1 mg/ml unless otherwise specified.
Virus preparation, cell transduction and western blot analysis Lentiviruses were produced as described elsewhere (Vigna and Naldini, 2000) . For immunoprecipitation, homogenized tumor samples were lysed with extraction buffer (EB) buffer (Giordano et al., 2002) . Cleared tumor lysates were immunoprecipitated for 2 h at 41C with the indicated antibody. For total protein analysis, cells were lysed and protein quantification was performed using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Primary antibodies: a-phosphotyrosine (Upstate Biotechnology, Charlottesville, VA, USA); a-Actin (Santa Cruz Biotec., Santa Cruz, CA, USA); a-MET (DL21 mAb) (Prat et al., 1991) ; a-AKT, a-p42/44 MAPK and a-phospho-p42/44 MAPK (Cell Signalling Technology, Beverly, MA, USA); a-phospho-AKT (Ser473) (New England Biolabs, Beverly, MA, USA). Secondary antibodies were purchased from Amersham (Arlington Heights, VA, USA). Detection was performed with ECL system (Amersham).
Real-time analysis
Decrease of MET mRNA level was determined by real-time quantitative PCR with ABI PRISM 7900HT (Applied Biosystems, Milan, Italy). TaqMan probes for MET and for the RNAseP housekeeping gene were supplied by Applied Biosystems.
Biological assays
For growth assays, experiments were performed as in (Valabrega et al., 2005) . For cell-cycle analysis, the percentage of proliferating cells was determined by assessment of DNA content after staining with propidium iodide (PI) using DNAcon3 kit (CONSUL TS, Orbassano, Italy) and following manufacturer's instructions. PI incorporation was analysed using a FACScalibur instrument equipped with the Doublet Discriminator Module (Becton Dickinson).
Analysis of colony formation in soft agar and evaluation of branching morphogenesis were performed as in (Giordano et al., 2002) . Matrigel invasion assays were performed as in (Trusolino et al., 2001) .
Xenograft transplantation experiments
Lentivirus-transduced tumor cells were injected subcutaneously into the right posterior flanks of 6-week-old immunodeficient nu À/À female mice on a Swiss CD-1 background (Charles River Laboratories, Lecco, Italy). The number of cells injected per mouse varied according the experiments (from 7 Â 10 6 to 3 Â 10 6 ). Tumor volume was calculated as described (Michieli et al., 2004) . At the end of the observation period, tumors were weighed, and lung nodules were contrasted with black India ink to facilitate assignment of scores. In the lung colony assay, GTL16 (1.25 Â 10 6 cells/mouse) were injected in the tail veins of nude mice. Paraffin-embedded sections of the lungs were stained with H&E and underwent histological analysis. Whole lung parenchymas were examined by analysing slices every 20 mm; in each slice, the presence and the extension of the metastatic deposit was assessed, according to the procedure routinely used by pathologists to evaluate the presence of micrometastases in distal organs. Tumor emboli were considered as a separate group (grade 1).
Immunohistochemical staining was performed using standard techniques (Michieli et al., 2004) . Primary antibodies: phospho-MET (Tyr1234/1235) antibody (Cell Signaling); Green Fluorescent Protein antibody (Invitrogen); KI-67 antibody, clone KI-67 (DAKO). TUNEL analysis of tumor samples was performed according to the manufacturer's instructions (In Situ Cell Death Detection Kit, TMR red, Roche, Manheim, Germany). All the experiments were performed on groups of six animals per experimental point. All animal procedures were approved by the Ethical Commission of the University of Torino, Italy, and by the Italian Ministry of Health.
Statistics
Results are means of at least three different experiments þ s.e.m. Comparisons were made using the two-tailed Student's t-test.
